Galectin Therapeutics (GALT) Cash from Financing Activities (2010 - 2026)
Galectin Therapeutics' quarterly Cash from Financing Activities came in at $257000.0 in Q1 2026, down 97.9% quarter-over-quarter from $12.2 million in Q4 2025.
Galectin Therapeutics has reported Cash from Financing Activities for 17 years, with the latest figure at $257000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $257000.0; the trailing twelve-month figure through Mar 2026 stood at $26.7 million (up 25.93% YoY), and the FY2025 full-year result was $26.5 million, down 15.22% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $257000.0, down from $12.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $12.9 million in Q2 2025, with the low at $257000.0 in Q1 2026.
- Average Cash from Financing Activities over 5 years is $8.3 million, with a median of $10.0 million recorded in 2022.
- Year-over-year, Cash from Financing Activities sank 91.49% in 2024 and jumped 1337.96% in 2025.
- Tracing GALT's Cash from Financing Activities over 5 years: stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then slumped by 91.49% to $851000.0 in 2024, then jumped by 1337.96% to $12.2 million in 2025, then plunged by 97.9% to $257000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $257000.0 (Q1 2026), $12.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 257,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 257,000.00 |
| Mar 31, 2026 | 257,000.00 |
| Dec 31, 2025 | 12.24 Mn |
| Dec 31, 2025 | 12.24 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 12.94 Mn |
| Jun 30, 2025 | 12.94 Mn |
| Dec 31, 2024 | 851,000.00 |
| Dec 31, 2024 | 851,000.00 |
| Sep 30, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 10.38 Mn |
| Jun 30, 2024 | 10.38 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | 10.03 Mn |
| Sep 30, 2023 | 10.03 Mn |
| Jun 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | 10.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Dec 31, 2022 | 10.00 Mn |
| Dec 31, 2022 | 10.00 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Jun 30, 2021 | 16.82 Mn |
| Jun 30, 2021 | 16.82 Mn |
| Jun 30, 2020 | 44,000.00 |
| Jun 30, 2020 | 44,000.00 |
| Mar 31, 2020 | 219,000.00 |
| Mar 31, 2020 | 219,000.00 |
| Dec 31, 2019 | 902,000.00 |
| Dec 31, 2019 | 902,000.00 |
| Sep 30, 2019 | -231,000.00 |
| Sep 30, 2019 | -231,000.00 |
| Jun 30, 2019 | 47.40 Mn |
| Jun 30, 2019 | 47.40 Mn |
| Mar 31, 2019 | 2.00 Mn |
| Mar 31, 2019 | 2.00 Mn |
| Dec 31, 2018 | 124,000.00 |
| Dec 31, 2018 | 124,000.00 |
| Sep 30, 2018 | 1.22 Mn |
| Sep 30, 2018 | 1.22 Mn |
| Jun 30, 2018 | 9.59 Mn |
| Jun 30, 2018 | 9.59 Mn |
| Mar 31, 2018 | 4.45 Mn |
| Mar 31, 2018 | 4.45 Mn |
| Dec 31, 2017 | -1,000.00 |
| Dec 31, 2017 | -1,000.00 |
| Sep 30, 2017 | 954,000.00 |
| Sep 30, 2017 | 954,000.00 |
| Jun 30, 2017 | 485,000.00 |
| Jun 30, 2017 | 485,000.00 |
| Mar 31, 2017 | 2.15 Mn |
| Mar 31, 2017 | 2.15 Mn |
| Dec 31, 2016 | 4.17 Mn |
| Dec 31, 2016 | 4.17 Mn |
| Sep 30, 2016 | 1.50 Mn |
| Sep 30, 2016 | 1.50 Mn |
| Dec 31, 2015 | 9.13 Mn |
| Dec 31, 2015 | 9.13 Mn |
| Sep 30, 2015 | 41,000.00 |
| Sep 30, 2015 | 41,000.00 |
| Mar 31, 2015 | 4.53 Mn |
| Mar 31, 2015 | 4.53 Mn |
| Dec 31, 2014 | 1.04 Mn |
| Dec 31, 2014 | 1.04 Mn |
| Sep 30, 2014 | 60,000.00 |
| Sep 30, 2014 | 60,000.00 |
| Jun 30, 2014 | 241,000.00 |
| Jun 30, 2014 | 241,000.00 |
| Mar 31, 2014 | 30.12 Mn |
| Mar 31, 2014 | 30.12 Mn |
| Dec 31, 2013 | 2.42 Mn |
| Dec 31, 2013 | 2.42 Mn |
| Sep 30, 2013 | 6.10 Mn |
| Sep 30, 2013 | 6.10 Mn |
| Jun 30, 2013 | 13,000.00 |
| Jun 30, 2013 | 13,000.00 |
| Mar 31, 2013 | 77,000.00 |
| Mar 31, 2013 | 77,000.00 |
| Mar 31, 2012 | 10.40 Mn |
| Mar 31, 2012 | 10.40 Mn |
| Sep 30, 2011 | 1.22 Mn |
| Sep 30, 2011 | 1.22 Mn |
| Jun 30, 2011 | 2.56 Mn |
| Jun 30, 2011 | 2.56 Mn |
| Mar 31, 2011 | 2.42 Mn |
| Mar 31, 2011 | 2.42 Mn |
| Dec 31, 2010 | 3.66 Mn |
| Dec 31, 2010 | 3.66 Mn |
| Sep 30, 2010 | 778,000.00 |
| Sep 30, 2010 | 778,000.00 |